HIIT Trial for Liver Disease, Los Ríos, Apr 27
Summary
ClinicalTrials.gov registered a single-blind randomized clinical trial evaluating high-intensity interval training (HIIT) on liver health in adults with overweight or obesity. The study will enroll 30 adults aged 18-59 from the Los Ríos Region, Chile, with BMI >25 kg/m² and chronic conditions such as dyslipidemia, diabetes, or hypertension. Participants will be randomized to HIIT (n=15) or a non-trained control group (n=15) for an 8-week intervention period.
“The HIIT intervention will last 8 weeks, with 2 to 3 sessions per week, each session lasting 30 minutes.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new clinical trial (NCT07552727) has been registered on ClinicalTrials.gov, proposing a single-blind randomized controlled study to evaluate the effects of HIIT on liver health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). The 8-week intervention involves 2-3 sessions per week with five 2.5-minute bouts at 80% heart rate reserve, using FibroScan for detecting and monitoring hepatic changes. Investigators conducting exercise-based interventions for metabolic liver disease and researchers studying MASLD should monitor the trial for results publication upon completion in April 2026.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Rehabilitation With Exercise-Based Intervention for Nonalcoholic Chronic Hepatic Esteatosis
N/A NCT07552727 Kind: NA Apr 27, 2026
Abstract
Specific Aim 5 proposes a single-blind randomized clinical trial designed to evaluate the effects of high-intensity interval training (HIIT) on liver health in adults with overweight or obesity, while also assessing the usefulness of FibroScan as a tool for detecting and monitoring hepatic changes. The study is grounded in the idea that HIIT may improve liver status in individuals with metabolic dysfunction-associated steatotic liver disease, even in the absence of major weight loss, and that FibroScan could serve not only as a diagnostic method but also as a follow-up instrument during conservative treatment.
The sample will include 30 adults from the Los Ríos Region, aged 18 to 59 years, with BMI >25 kg/m² and chronic noncommunicable conditions such as dyslipidemia, diabetes, or hypertension, provided they are fit for exercise. Participants will be randomly assigned to either an intervention group (HIIT, n=15) or a non-trained control group (n=15). Recruitment will be community-based, using posters and social media, and eligibility will be screened with the PAR-Q+ questionnaire. Individuals with excessive alcohol intake, liver disease of other etiologies, pregnancy, or contraindications to exercise will be excluded.
The HIIT intervention will last 8 weeks, with 2 to 3 sessions per week, each session lasting 30 minutes. The protocol consists of five 2.5-minute bouts at 80% of heart rate reserve, interspersed with 2.5-minute active recovery periods at 20% of heart rate ...
Conditions: Metabolic Adaptation to High-Intensity Interval Training, Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
Interventions: High-intensity interval training
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.